Form 4: Pontifax Management Boosts LBRX Stake

Pontifax Management 4 G.P. (2015) Ltd., a 10% owner and director, acquired 1,000,000 shares of LB PHARMACEUTICALS INC common stock at $15 per share, increasing its beneficial ownership to 1,411,681 shares.

Summary

• Pontifax Management 4 G.P. (2015) Ltd., a director and 10% owner of LB PHARMACEUTICALS INC, reported significant changes in its beneficial ownership.
• On September 12, 2025, Pontifax converted 10,000,000 shares of Series C Preferred Stock into 411,681 shares of Common Stock. This conversion occurred immediately prior to the closing of the Issuer's initial public offering.
• On the same date, Pontifax purchased an additional 1,000,000 shares of Common Stock at a price of $15 per share.
• Following these transactions, Pontifax Management 4 G.P. (2015) Ltd. beneficially owns a total of 1,411,681 shares of LB PHARMACEUTICALS INC Common Stock.
• The ownership is indirect, held through Pontifax (Israel) VI Limited Partnership and Pontifax (Cayman) VI Limited Partnership, with Messrs. Tomer Kariv and Ran Nussbaum as Managing Partners sharing voting and investment power.

Sentiment

Score: 8

Explanation: A significant purchase by a major insider (10% owner and director) indicates strong confidence in the company's future, especially in the context of an IPO.

Positives

• A significant purchase of 1,000,000 shares of common stock by a 10% owner and director, Pontifax Management 4 G.P. (2015) Ltd., indicates strong insider confidence in LB PHARMACEUTICALS INC's future prospects.
• The conversion of Series C Preferred Stock into common stock, alongside the purchase, consolidates Pontifax's equity position in the company.

Future Outlook

NA

Industry Context

This transaction reflects a significant insider investment in the biotechnology/pharmaceutical sector, often seen as a vote of confidence in a company's pipeline or market strategy, particularly around an initial public offering.

Related Party Transactions

• The transactions involve Pontifax Management 4 G.P. (2015) Ltd., a 10% owner and director of LB PHARMACEUTICALS INC, making it a related party transaction.

Stakeholder Impact

• Shareholders: Increased confidence due to significant insider buying, potentially signaling positive future performance.
• Company: Strengthened capital base if the purchase was a direct issuance, and a strong vote of confidence from a major investor.

Key Dates

Recommendation

The substantial purchase of 1,000,000 shares at $15 per share by Pontifax Management 4 G.P. (2015) Ltd., a 10% owner and director, signals strong insider conviction in LB PHARMACEUTICALS INC's valuation and future prospects, particularly following its initial public offering. This significant insider buying activity is a highly bullish indicator for investors.

Keywords

LB PHARMACEUTICALS INC, LBRX, Pontifax Management, Insider Buying, Form 4, Beneficial Ownership, Common Stock, Series C Preferred Stock, IPO, Biotechnology, Pharmaceuticals